AbbVie Inc (ABBV)

64.17
0.34 0.53
NYSE : Health Care
Prev Close 64.51
Open 64.60
Day Low/High 64.11 / 64.71
52 Wk Low/High 45.45 / 68.12
Volume 5.53M
Avg Volume 8.02M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 105.22B
EPS 3.10
P/E Ratio 18.62
Div & Yield 2.28 (3.50%)

Latest News

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

Pharma Has History of Price Gouging, Mylan Should Be No Surprise

While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble

Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble

The pharma company has been increasing the price of the epinephrine injector since 2007, so why are people finally taking notice?

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.

TG Therapeutics Looks Like a Healthy Play

TG Therapeutics Looks Like a Healthy Play

Small biotech tanked on weak earnings, but still seems promising.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Earnings Winners and Losers, and What It Means for the Portfolio

A review of earnings for portfolio names, along with upcoming dividend reminders.

Stocks Retreat From Records as Health Care Slumps

Stocks Retreat From Records as Health Care Slumps

Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.

Health Care Drags Stocks Away From Records

Health Care Drags Stocks Away From Records

Stocks pull lower on Monday morning as a selloff in health care sours the jobs-inspired rally that pushed benchmark indices to record highs last week.

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Stocks secure robust gains after the latest labor market snapshot breezes past expectations.

AbbVie (ABBV) Stock Up, Sues Amgen to Block Humira Copycat

AbbVie (ABBV) Stock Up, Sues Amgen to Block Humira Copycat

AbbVie is suing Amgen in an attempt to block the rival biopharmaceutical company from producing a copycat of its Humira drug.

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.

'Mad Money' Lightning Round: I'm Still With Opko Health

'Mad Money' Lightning Round: I'm Still With Opko Health

Cramer wants you to stick with Abbvie and says Cepheid is working.

Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid

Jim Cramer's 'Mad Money' Recap: Four Winning Themes, Four to Avoid

Cramer has seen enough in this earnings season to come to some conclusions on what's working and what isn't.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

AbbVie Is Headed Even Higher -- Here's How to Trade It Now

AbbVie Is Headed Even Higher -- Here's How to Trade It Now

AbbVie is setting up well for a run back up to its 2015 highs.

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

The drug maker continued to rally Monday.

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

Gilead Sciences Has No Cure in Sight for Increasing Competition

Gilead Sciences Has No Cure in Sight for Increasing Competition

In the last year, shares of Gilead Sciences are down 32%. With competition increasing for its hepatitis-C treatment, it is unlikely shareholders will see any relief.

S&P 500 Ends Blockbuster July Near Records

S&P 500 Ends Blockbuster July Near Records

The S&P 500 ends a record-making July with only slight gains on Friday.

AbbVie Shares Rise on Revenue Jump

AbbVie Shares Rise on Revenue Jump

Shares of AbbVie were up Friday after the company reported a big jump in revenue.

AbbVie Is Still Pointed Up, for Now

AbbVie Is Still Pointed Up, for Now

Consider raising your sell stop protection to a close below $61.

S&P 500 on Track for July Gains as Alphabet, Amazon Climb

S&P 500 on Track for July Gains as Alphabet, Amazon Climb

The S&P 500 moves higher on Friday, on track to end the month on a high, as Alphabet and Amazon rally on positive earnings.

Trending Tickers: BUD, ABBV, SRCL, EXPE

Trending Tickers: BUD, ABBV, SRCL, EXPE

The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.

Abbvie Plans to Defend Humira, Sees Upside in Oncology and Hep C Treatments

Abbvie Plans to Defend Humira, Sees Upside in Oncology and Hep C Treatments

The company reported better-than-expected earnings and revenue Friday.